The gatekeepers of effectiveness.
Mark
M
Ratner
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D003695:Delivery of Health Care / Q000331:legislation & jurisprudence* / Q000458:organization & administration; D017277:Drug Approval / Q000331:legislation & jurisprudence* / Q000458:organization & administration; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D018802:Patient-Centered Care / Q000331:legislation & jurisprudence* / Q000458:organization & administration; D016896:Treatment Outcome; D014481:United States
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab